pointofcar
test
need
screen
head
neck
squamou
cell
carcinoma
hnscc
malign
luciferas
immunoprecipit
system
lip
employ
lightemit
protein
use
examin
serum
antibodi
sever
cancerassoci
target
blood
donor
control
subject
colon
cancer
cc
hnscc
assess
antibodi
wild
type
tumor
antigen
show
approxim
cc
hnscc
patient
seroposit
addit
humor
respons
two
mutant
gener
track
antibodi
respons
seen
wild
type
analysi
antibodi
highli
specif
biomark
malign
oncoprotein
reveal
seroposit
blood
donor
cc
patient
howev
hnscc
patient
show
seroposit
overlap
detect
seroposit
subject
use
neodymium
magnet
ultrarapid
lipstick
test
antibodi
per
hnscc
sampl
demonstr
almost
diagnost
perform
sensit
specif
lip
test
h
addit
improv
standard
need
result
highlight
possibl
use
approach
diagnosi
hnscc
keyword
tumor
antigen
head
neck
cancer
human
papilloma
luciferas
immunoprecipit
system
lip
interest
develop
pointofcar
test
oral
health
set
clinic
detect
head
neck
squamou
cell
carcinoma
hnscc
base
unchang
surviv
rate
hnscc
need
better
diagnost
prognost
tool
one
potenti
approach
exploit
patient
antibodi
respons
direct
tumor
antigen
cancerrel
antibodi
tumor
antigen
thought
aris
protein
overexpress
alter
splice
form
mutat
protein
modif
andor
repres
viral
oncogen
studi
hnscc
cancer
detect
antibodi
wellcharacter
tumor
antigen
commonli
mutat
cancer
addit
human
papillomaviru
hpv
particularli
genotyp
directli
involv
caus
cancer
subset
hnscc
patient
well
cervic
cancer
anal
cancer
particularli
relev
find
serum
antibodi
oncoprotein
highli
specif
biomark
presenc
hpvdriven
tumor
antibodi
protein
found
patient
harbor
hpvassoci
cancer
found
subject
hpv
infect
alon
without
malign
healthi
control
interestingli
antibodi
detect
decad
futur
diagnosi
hnscc
highlight
potenti
import
role
earli
biomark
cancer
screen
other
use
fluid
phase
immunoassay
employ
luciferasetag
recombin
fusion
protein
call
luciferas
immunoprecipit
system
lip
diagnost
purpos
owe
enhanc
present
linear
conform
antigen
epitop
solut
lip
immunoassay
often
higher
sensit
specif
dynam
rang
detect
solidphas
immunoassay
antibodi
profil
gener
lip
highli
inform
elucid
patient
subset
autoimmun
infecti
diseas
discoveri
new
autoimmun
condit
identif
novel
pathogen
diagnosi
pandem
virus
recent
streamlin
version
lipstick
employ
magnet
captur
immun
complex
abl
quickli
accur
measur
diagnost
antibodi
associ
six
differ
autoimmun
infecti
diseas
includ
diagnosi
syndrom
report
describ
studi
use
lip
assay
detect
cancerassoci
antibodi
respons
tumor
antigen
includ
protein
addit
detect
hpv
antibodi
lipstick
technolog
enabl
rapid
diagnosi
hpvassoci
hnscc
inform
written
consent
obtain
subject
accord
human
experiment
guidelin
depart
health
human
servic
irbapprov
protocol
studi
conduct
accord
principl
express
declar
helsinki
human
sampl
util
report
repres
deidentifi
serum
specimen
annot
data
healthi
volunt
hv
blood
donor
control
obtain
nih
blood
bank
clinic
center
nih
bethesda
maryland
entitl
collect
distribut
blood
compon
healthi
donor
vitro
research
use
serum
sampl
colon
cancer
cc
system
lupu
erythematosu
sle
hnscc
patient
use
report
obtain
convers
bio
genom
way
suit
huntsvil
alabama
subject
provid
written
inform
consent
western
institut
review
board
approv
convers
bio
human
serum
sampl
convers
bio
collect
process
distribut
full
ethic
regulatori
complianc
site
collect
includ
independ
ethic
review
institut
review
board
approv
appropri
independ
regulatori
review
convers
bioethic
review
hv
control
n
nih
blood
bank
repres
subject
averag
age
year
male
subject
hnscc
n
averag
age
cancer
diagnosi
year
male
clinic
inform
cc
n
avail
serum
sampl
sle
patient
n
averag
age
year
femal
previous
describ
construct
renilla
luciferas
ruc
chimer
fusion
protein
use
two
known
cancer
mutant
protein
also
gener
code
sequenc
protein
subclon
vector
gener
ctermin
hpv
fusion
protein
essenti
describ
antigen
cdna
also
subclon
vector
express
nanoluc
fusion
protein
highli
activ
luciferas
integr
describ
construct
confirm
dna
sequenc
essenti
describ
lip
assay
perform
approxim
h
use
plate
format
room
temperatur
briefli
recombin
luciferas
antigen
lysat
produc
transfect
dna
plasmid
construct
cell
activ
light
unit
lu
determin
tube
luminomet
turner
design
initi
test
buffer
dilut
human
sera
equival
luciferaseantigen
cell
extract
input
approxim
million
lu
dilut
buffer
ad
well
microtit
plate
h
next
suspens
ultralink
protein
ag
bead
pierc
biotechnolog
rockford
il
usa
ad
bottom
well
filter
ht
plate
millipor
bedford
usa
antigenantibodi
reaction
mixtur
move
filter
plate
incub
h
rotari
shaker
multipl
wash
step
retain
protein
ag
bead
perform
complet
wash
step
lu
measur
berthold
lb
centro
micropl
luminomet
berthold
technolog
bad
wildbad
germani
use
either
coelenterazin
furimazin
substrat
promega
madison
wi
usa
detect
renilla
luciferas
nanoluc
activ
respect
lipstick
technolog
employ
cell
extract
contain
protein
investig
ultrarapid
diagnosi
hpvassoci
hnscc
compar
previous
report
protocol
slightli
modifi
version
assay
use
chang
order
reagent
addit
produc
higher
signal
perform
modifi
version
assay
dilut
serum
sampl
water
ad
fusion
protein
cell
extract
million
lu
ml
microfug
tube
dilut
paramagnet
bead
thermo
scientificpierc
protein
ag
magnet
bead
waltham
usa
dilut
water
ad
reaction
mix
tap
two
time
dispers
magnet
bead
buffer
pipet
reaction
mixtur
tube
immedi
vortex
diamet
neodymium
magnet
stick
k
g
magnet
pipersvil
pa
usa
immers
tube
contain
bead
collect
immun
complex
magnet
remov
dip
twice
wash
buffer
lastli
magnet
stick
place
tube
preload
nanoglow
substrat
promega
luminesc
glow
measur
tube
luminomet
integr
time
graphpad
prism
softwar
san
diego
ca
usa
employ
data
plot
statist
analysi
nonparametr
mannwhitney
u
test
use
compar
antibodi
level
among
group
statist
signific
p
shown
figur
calcul
sensit
specif
cutoff
limit
antigen
deriv
mean
valu
plu
three
standard
deviat
healthi
blood
donor
control
use
lip
technolog
antibodi
wild
type
evalu
serum
sampl
cohort
includ
hv
n
cc
n
hnscc
n
test
extract
contain
renilla
luciferas
ruc
control
protein
reveal
low
level
antibodi
hv
cc
hnscc
subject
figur
lip
analysi
protein
target
demonstr
rel
low
antibodi
level
hv
wherea
small
number
patient
cc
hnscc
much
higher
antibodi
level
figur
determin
seroposit
antibodi
cancer
subject
cutoff
valu
assign
base
antibodi
valu
correspond
mean
plu
three
standard
deviat
hv
control
shown
cc
hnscc
patient
seroposit
diagnost
specif
figur
three
subject
cc
two
hnscc
show
seroposit
autoantibodi
cutoff
valu
determin
whether
antibodi
signal
detect
antibodi
might
enhanc
two
cancer
mutant
variant
test
figur
howev
shown
antibodi
profil
part
show
similar
profil
wild
type
protein
due
known
high
preval
hpvassoci
hnscc
antibodi
protein
analyz
lip
analysi
antibodi
reveal
low
level
hv
cc
patient
similar
buffer
blank
figur
data
shown
howev
eight
hnscc
patient
show
high
antibodi
level
approxim
time
higher
correspond
mean
level
hv
control
figur
lip
analysi
antibodi
second
antigen
also
detect
seroposit
hv
control
cc
patient
detect
seven
seroposit
hnscc
patient
overlap
seroposit
subject
figur
test
hpv
antigen
renilla
luciferas
fusion
protein
reveal
pattern
hv
cc
show
seroneg
yet
detect
nine
hnscc
seroposit
data
shown
confirm
result
differ
report
nanoluc
employ
detect
antibodi
shown
figur
test
also
reveal
nine
hnscc
subject
seroposit
test
twenti
sle
patient
anoth
set
diseas
control
detect
seroposit
support
observ
antibodi
respons
associ
hnscc
patient
data
shown
inspect
hpv
antibodi
profil
hnscc
subject
reveal
nine
subject
seroposit
eight
overlap
subject
seroposit
subject
seroposit
protein
lastli
presenc
nine
seroposit
sampl
hnscc
group
due
known
high
preval
hpvassoci
hnscc
antibodi
protein
analyz
lip
analysi
antibodi
reveal
low
level
hv
cc
patient
similar
buffer
blank
figur
data
shown
howev
eight
hnscc
patient
show
high
antibodi
level
approxim
time
higher
correspond
mean
level
hv
control
figur
lip
analysi
antibodi
second
antigen
also
detect
seroposit
hv
control
cc
patient
detect
seven
seroposit
hnscc
patient
overlap
seroposit
subject
figur
test
hpv
antigen
renilla
luciferas
fusion
protein
reveal
pattern
hv
cc
show
seroneg
yet
detect
nine
hnscc
seroposit
data
shown
confirm
result
differ
report
nanoluc
employ
detect
antibodi
shown
figur
test
also
reveal
nine
hnscc
subject
seroposit
test
twenti
sle
patient
anoth
set
diseas
control
detect
seroposit
support
observ
antibodi
respons
associ
hnscc
patient
data
shown
inspect
hpv
antibodi
profil
hnscc
subject
reveal
nine
subject
seroposit
eight
overlap
subject
seroposit
subject
seroposit
protein
lastli
presenc
nine
seroposit
sampl
hnscc
group
statist
differ
complet
absenc
seroposit
either
hv
group
subject
colon
cancer
fischer
exact
test
p
base
substanti
differ
antibodi
level
seen
lip
hpvneg
hpvposit
hnscc
sampl
sought
determin
whether
rapid
lipstick
format
employ
fusion
protein
could
use
detect
antibodi
hnscc
group
figur
oneminut
lipstick
assay
gener
antibodi
signal
differenti
hv
hpvneg
hnscc
patient
hpvposit
hnscc
sampl
mean
level
antibodi
hnscc
sampl
significantli
higher
p
valu
seen
twenti
hv
control
figur
use
cutoff
valu
base
mean
plu
three
standard
deviat
hv
control
reveal
diagnost
perform
sensit
specif
detect
antibodyposit
hnscc
patient
rapid
format
moreov
antibodi
level
detect
lipstick
format
significantli
differ
p
hpvneg
hnscc
hpvposit
hnscc
case
data
shown
find
suggest
lipstick
test
potenti
diagnos
hnscc
use
lip
technolog
antibodybas
biomark
human
tumor
antigen
base
substanti
differ
antibodi
level
seen
lip
hpvneg
hpvposit
hnscc
sampl
sought
determin
whether
rapid
lipstick
format
employ
fusion
protein
could
use
detect
antibodi
hnscc
group
figur
oneminut
lipstick
assay
gener
antibodi
signal
differenti
hv
hpvneg
hnscc
patient
hpvposit
hnscc
sampl
mean
level
antibodi
hnscc
sampl
significantli
higher
p
valu
seen
twenti
hv
control
figur
use
cutoff
valu
base
mean
plu
three
standard
deviat
hv
control
reveal
diagnost
perform
sensit
specif
detect
antibodyposit
hnscc
patient
rapid
format
moreov
antibodi
level
detect
lipstick
format
significantli
differ
p
hpvneg
hnscc
hpvposit
hnscc
case
data
shown
find
suggest
lipstick
test
potenti
diagnos
hnscc
use
lip
technolog
antibodybas
biomark
human
tumor
antigen
antibodi
oncogen
hpv
investig
approxim
colon
cancer
hnscc
patient
harbor
statist
signific
autoantibodi
wild
type
consist
publish
studi
lip
profil
hpv
viral
protein
detect
high
preval
antibodi
respons
hnscc
hv
cc
sle
agreement
studi
consist
publish
report
antigen
found
higher
sensit
antigen
find
hnscc
subject
associ
cancer
approxim
match
known
preval
like
due
stochast
natur
small
cohort
particularli
encourag
quit
robust
detect
antibodi
lip
hnscc
subject
highlight
potenti
abil
assay
screen
antibodi
highthroughput
fashion
also
great
interest
rapid
point
care
test
infect
cancer
autoimmun
common
poc
direct
diagnost
antibodi
base
later
flow
microfluid
devic
one
recent
studi
show
microfluid
devic
coupl
immunoassay
detect
antibodi
moder
diagnost
sensit
specif
requir
least
hour
process
oneminut
lipstick
assay
perform
quit
well
detect
antibodi
associ
hnscc
hnscc
subject
show
rel
dramat
differ
neg
posit
sampl
subject
less
easili
detect
seroposit
fell
near
cutoff
valu
one
sampl
neg
anticip
improv
lipstick
assay
relat
antigen
design
assay
standard
enhanc
test
perform
one
limit
studi
rel
small
cohort
test
explor
whether
lipstick
detect
hpvassoci
hnscc
larger
wellcharacter
cohort
warrant
